Nebraska Clinical Trials Report — May 2026

For Nebraskans considering participation in clinical research, May 2026 presents a critical window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 41 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 9 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on heart health, digestive issues, and various forms of cancer are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart failure
• Irritable bowel syndrome with constipation (IBS-C)
• Amnio-Maxx
• Atrial fibrillation
• Autism spectrum disorder
• Benign prostatic hyperplasia (BPH)
• Cancer harboring BRAF alterations
• Breast cancer
• Cancer weight loss
• Castration resistant metastatic prostate cancer

Major Research Initiatives Launch in Nebraska

This month brings 2 new clinical trials to Nebraska, with a notable Phase 3 study from a major pharmaceutical company. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to cardiovascular conditions.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight. This is a significant opportunity for individuals in Nebraska to contribute to research on these interconnected conditions.

Both new trials this month are drug trials, reflecting a continued focus on pharmacological advancements in the industry. The other new trial is sponsored by Crinetics Pharmaceuticals Inc., further expanding the range of research opportunities available.

Opportunities for Healthy Volunteers and Diverse Participation

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 2 new trials launched this month, 1 is actively seeking healthy volunteers. This adds to the existing pool, bringing the total number of trials recruiting healthy participants statewide to 72. These studies are crucial for establishing baseline data and understanding drug effects in individuals without confounding health issues.

Participation in clinical trials is open to a wide range of individuals. Of the new trials launched this month, 1 includes older adults, ensuring that senior populations have ample opportunity to contribute to medical science. There are no new trials this month specifically for children, or that are female-only or male-only.

Nebraska's Evolving Research Landscape

This month, Nebraska saw the opening of 2 new clinical trials, a slower pace compared to the 12 trials that launched in April 2026 and the 11 in March 2026. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 722 clinical trials currently recruiting across 23 cities and 389 research sites.

The new research initiatives this month are concentrated in a single location, with both new trials opening in Lincoln. While this month's new trials are geographically focused, the overall research landscape in Nebraska remains widely distributed, with studies available in various communities across the state. This broad distribution ensures that residents in different regions have access to clinical trial participation.

New studies are exploring a range of conditions. This month's new trials are targeting:

• Healthy volunteers
• Heart failure
• Obesity

Both of the new studies are drug trials, indicating a continued emphasis on pharmacological interventions within the state's research efforts.

As we move through May, the focus will likely shift towards the ongoing enrollment in these significant Phase 3 trials and the 41 studies nearing their close dates, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Nebraska.